Allele Capital Partners

About Allele Capital Partners

Allele Capital Partners specializes in advising, investing in, and raising capital for private and public life science companies. They have a comprehensive focus on various disease areas, including neurology, rare diseases, oncology, and cardiovascular conditions. The firm is actively involved in multiple modalities of life science innovations such as gene therapy, RNA, small molecules, and biologics. For their investment strategy, Allele Capital Partners targets companies operating in sectors like PropTech, BioTech, FinTech & Financial Services, HealthTech & Fitness, Medical Devices & Hospital Services, Real Estate & Construction, Healthcare & Wellness, and Pharmaceutical & Medicine. They position themselves not only as investors but also as advisors and partners who believe in integrity and the power of life science innovations to significantly improve patient lives. Allele Capital Partners provides advisory services, merchant and investment banking expertise to clients in the U.S. and globally, working closely with their partners to prepare corporate strategies, refine pitches, and fine-tune corporate strategy and timelines. The fund has a minimum investment threshold of $100,000 and a maximum of $5,000,000, with a sweet spot around $1,500,000 for investments, covering stages from Seed to Series B. They distinguish themselves by offering a partnership approach, potentially reducing the cost and speed to access capital compared to traditional venture capital routes.Testimonials from clients within the life sciences domain praise Allele for their ability to act as an extension of the management team, for their fair terms of partnership, and for their substantial knowledge of science and capital markets. These testimonials underscore Allele's role in aiding companies through significant financial milestones and their deep understanding of and network in the sector. Allele Capital Partners is known for their impactful and hands-on approach to building and financing successful life science ventures, both private and public.